Which mutual funds hold Q-Line Biotech Limited?
1 fund houses holding · net +85,200 shares (+0.37 pp of equity) · Oct 2026 vs Sep 2026
1 fund houses holding · net +85,200 shares (+0.37 pp of equity) · Oct 2026 vs Sep 2026
Net bought by the tracked fund houses 3 months in a row, Aug 2026 to Oct 2026 (share count, each month against the one before; houses with both months, index and arbitrage funds left out).
| % of equity, Oct 2026 | Activity | Source | |||||
|---|---|---|---|---|---|---|---|
| Abakkus Mutual Fund | 1 | 5.14 lakh2.20% | 5.99 lakh2.57% | ▲ +85,200▲ +0.37 pp | 2.57% | Added bought 3 months in a row | Disclosure ↗ |
| Abakkus Mutual Fund | 1 | 5.14 lakh2.20% | 5.99 lakh2.57% | ▲ +85,200▲ +0.37 pp | 2.57% | Added | Disclosure ↗ |
No fund house is in this bucket for Oct 2026.
Shares as disclosed; % of equity uses 2.33 cr shares outstanding (NSE, 20 Nov 2026) for both months. "Not compared" = the fund house has no Sep 2026 portfolio.
| Scheme | Fund house | Shares | % of scheme | Rank in scheme | % of scheme vs Jul 2026 | Shares vs Jul 2026 | Months in a row |
|---|---|---|---|---|---|---|---|
| Abakkus Small Cap Fund | Abakkus Mutual Fund | 5.99 lakh | 0.92% | 56 of 64 (was 53) | −0.32 pp | +1.14 lakh | bought 3 months in a row |
Index and arbitrage schemes included. Rank: by value among the scheme's equity holdings (1 = largest). Jul 2026: the same scheme's portfolio three months before; shares in Oct 2026's units (split or bonus adjusted). Months in a row: months the scheme's share count went up (bought) or down (sold), each month against the one before.